AU2024221034A1 - Artificial mirna construct - Google Patents

Artificial mirna construct

Info

Publication number
AU2024221034A1
AU2024221034A1 AU2024221034A AU2024221034A AU2024221034A1 AU 2024221034 A1 AU2024221034 A1 AU 2024221034A1 AU 2024221034 A AU2024221034 A AU 2024221034A AU 2024221034 A AU2024221034 A AU 2024221034A AU 2024221034 A1 AU2024221034 A1 AU 2024221034A1
Authority
AU
Australia
Prior art keywords
sequence
mirna
construct
binding
seed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024221034A
Other languages
English (en)
Inventor
Hiroshi Asahara
Tomoki Chiba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Science Tokyo
Original Assignee
Institute of Science Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Science Tokyo filed Critical Institute of Science Tokyo
Publication of AU2024221034A1 publication Critical patent/AU2024221034A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2024221034A 2023-02-15 2024-02-14 Artificial mirna construct Pending AU2024221034A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023021890 2023-02-15
JP2023-021890 2023-02-15
PCT/JP2024/004958 WO2024172057A1 (ja) 2023-02-15 2024-02-14 人工ｍｉＲＮＡ構築物

Publications (1)

Publication Number Publication Date
AU2024221034A1 true AU2024221034A1 (en) 2025-10-02

Family

ID=92420145

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2024221034A Pending AU2024221034A1 (en) 2023-02-15 2024-02-14 Artificial mirna construct

Country Status (4)

Country Link
EP (1) EP4667571A1 (https=)
JP (1) JPWO2024172057A1 (https=)
AU (1) AU2024221034A1 (https=)
WO (1) WO2024172057A1 (https=)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008034123A2 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
JP2008206482A (ja) * 2007-02-27 2008-09-11 Hiroshima Univ 癌の浸潤を指標とした診断マーカーおよび癌治療遺伝子
GB0723246D0 (en) * 2007-07-03 2008-01-09 Barton Michelle p53 modulator
JP2011093892A (ja) * 2009-09-30 2011-05-12 Japan Health Science Foundation がん抑制的マイクロｒｎａを含む腫瘍増殖抑制剤
EP2842546A4 (en) * 2012-04-27 2015-12-30 Univ Tokyo PHARMACEUTICAL COMPOSITION WITH UNIT STRUCTURE FOR NUCLEIC ACID RELIEF
JP2015089874A (ja) * 2013-11-05 2015-05-11 国立大学法人大阪大学 ｍｉＲ−３４０を用いた大腸癌の治療剤
CN109055522A (zh) * 2018-07-03 2018-12-21 吉林大学 C4orf38在制备用于检测或治疗神经性疼痛的产品中的应用
AU2019390097A1 (en) * 2018-11-30 2021-07-15 Kyowa Kirin Co., Ltd. Nucleic acid conjugate
WO2021159008A2 (en) * 2020-02-07 2021-08-12 Maze Therapeutics, Inc. Compositions and methods for treating neurodegenerative diseases
WO2021239825A1 (en) * 2020-05-27 2021-12-02 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of cnnm4 in a cell
CN113717971B (zh) * 2021-08-10 2025-03-28 南通大学 PGK1靶向siRNA干扰库及其应用
EP4480494A4 (en) * 2022-02-16 2026-03-11 Univ Nat Corp Tokyo Medical & Dental COMPOSITION INTENDED FOR USE IN THE TREATMENT OF CANCER, INFLAMMATORY DISEASES OR OBESITY, AND ITS USE

Also Published As

Publication number Publication date
JPWO2024172057A1 (https=) 2024-08-22
EP4667571A1 (en) 2025-12-24
WO2024172057A1 (ja) 2024-08-22

Similar Documents

Publication Publication Date Title
EP2839005B1 (en) Mirna modulators of thermogenesis
EP3426781B1 (en) Micrornas and methods of their use
JP5923466B2 (ja) Ｃｎｓ状態の治療
EP2208499A1 (en) Nucleic acid capable of regulating the proliferation of cell
BR112021008982A2 (pt) nanopartículas de lipídio, composição farmacêutica, método para distribuir um ácido nucleico a uma célula e métodos para tratar uma doença
EP2123752A2 (en) Novel nucleic acid
US20100113562A1 (en) Therapeutic targets and molecules
EP2374884A2 (en) Human miRNAs isolated from mesenchymal stem cells
EP2298359A1 (en) Nucleic acid capable of controlling degranulation of mast cell
US10612020B2 (en) Artificial mimic miRNA for controlling gene expression, and use of same
US20110118337A1 (en) Method of Using Compositions Comprising MIR-192 and/or MIR-215 for the Treatment of Cancer
EP2683411B1 (en) Methods of using microrna-26a to promote angiogenesis
US20140356459A1 (en) Micrornas and uses thereof
EP2774989B1 (en) Double-stranded nucleic acid molecule for gene expression control
JP6974872B2 (ja) ヘテロ二本鎖型ａｎｔｉｍｉＲ
AU2024221034A1 (en) Artificial mirna construct
WO2016192669A1 (zh) 通过miR-96进行减肥、降血糖和降血脂的方法和药物及其应用
US20230203493A1 (en) Biomarkers Related to Oral Squamous Cell Carcinoma and Methods of Diagnosis and Treatment Thereof
CN116096420A (zh) 利用miR-33b抑制物质的动脉瘤的预防或治疗
CN118001292A (zh) 靶向rna的组合物及其用途
CN102988985B (zh) miR-146a作为调节血管生长靶标的用途
WO2017022650A1 (ja) 修飾ｓｉＲＮＡ及びそれを含む医薬組成物
US20240401048A1 (en) Microrna-541-3p as a therapeutic agent as well as znf101 and casz1 as therapeutic targets to lower plasma ldl-c, increase plasma hdl-c, and reduce atherosclerosis
US20120065246A1 (en) Rna molecules and therapeutic uses thereof
CN101011575A (zh) 预防和治疗动脉粥样硬化病的rna干扰药物